|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
ALKALINIZATION OF URINE PROLONGS THE HALF LIFE OF SYMPATHOMIMETICS AND SO ACTION
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
MAOI INHIBIT THE METABOLISM OF SYMPATHOMIMETICS WHICH CAN LEAD TO DANGEROUS ENHANCEMENT OF THEIR PRESSOR EFFECTS CAUSING HEADACHE, HIGH BLOOD PRESSURE / HYPERTENSIVE CRISIS. A VARIETY OF NEUROLOGICAL TOXIC EFFECTS & MALIGNANT HYPERPYREXIA CAN OCCUR
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
INOTROPIC EFFECTS OF THE DRUG ARE REVERSED BY BETABLOCKERS & THEN THERE MAY BE VASOCONSTRICTION & AN INCREASE IN BLOOD PRESSURE DUE TO DOPAMINES ALPHA AGONIST EFFECTS
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
ADDITIVE PRESSOR EFFECT. USE WITH DOPAMINE OR DOBUTAMINE WAS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF GANGRENE IN BOTH HANDS & FEET
|
ADDITIVE PRESSOR EFFECT. USE WITH DOPAMINE OR DOBUTAMINE WAS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF GANGRENE IN BOTH HANDS & FEET
|
ADDITIVE PRESSOR EFFECT. USE WITH DOPAMINE OR DOBUTAMINE WAS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF GANGRENE IN BOTH HANDS & FEET
|
ADDITIVE PRESSOR EFFECT. USE WITH DOPAMINE OR DOBUTAMINE WAS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF GANGRENE IN BOTH HANDS & FEET
|
ADDITIVE PRESSOR EFFECT. USE WITH DOPAMINE OR DOBUTAMINE WAS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF GANGRENE IN BOTH HANDS & FEET
|
ADDITIVE PRESSOR EFFECT. USE WITH DOPAMINE OR DOBUTAMINE WAS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF GANGRENE IN BOTH HANDS & FEET
|
ADDITIVE PRESSOR EFFECT. USE WITH DOPAMINE OR DOBUTAMINE WAS ASSOCIATED WITH SUBSEQUENT DEVELOPMENT OF GANGRENE IN BOTH HANDS & FEET
|
SYMPATHOMIMETICS MAY ANTAGONISE THE HYPOTENSIVE EFFECTS OF METHYLDOPA
|
SYMPATHOMIMETICS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
SYMPATHOMIMETICS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CONCURRENT ADMINISTRATION WITH ADRENALINE OR OTHER SYMPATHOMIMETICS MAY CAUSE VENTRICULAR FIBRILLATION
|
CONCURRENT ADMINISTRATION WITH ADRENALINE OR OTHER SYMPATHOMIMETICS MAY CAUSE VENTRICULAR FIBRILLATION
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
ADRENALINE & SIMILAR DRUGS CONCOMITANT ADMINISTRATION MAY LEAD TO SEVERE HYPERTENSION & TACHYCARDIA DUE TO UNAPPOSED BETA ADRENOCEPTOR STIMULATION
|
ADRENALINE & SIMILAR DRUGS CONCOMITANT ADMINISTRATION MAY LEAD TO SEVERE HYPERTENSION & TACHYCARDIA DUE TO UNAPPOSED BETA ADRENOCEPTOR STIMULATION
|
ADRENALINE & SIMILAR DRUGS CONCOMITANT ADMINISTRATION MAY LEAD TO SEVERE HYPERTENSION & TACHYCARDIA DUE TO UNAPPOSED BETA ADRENOCEPTOR STIMULATION
|
ADRENALINE & SIMILAR DRUGS CONCOMITANT ADMINISTRATION MAY LEAD TO SEVERE HYPERTENSION & TACHYCARDIA DUE TO UNAPPOSED BETA ADRENOCEPTOR STIMULATION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS ARRHYTHMOGENIC EFFECT IS POTENTIATED BY THE DRUG
|
SYMPATHOMIMETICS ARRHYTHMOGENIC EFFECT IS POTENTIATED BY THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION MAY POTENTIATE HYPERTENSIVE EFFECT OF THE DRUG
|